A cup of coffee with … Nathalie van Hooijdonk
"I’ve been working at Pivot Park now for about five weeks and I already like the atmosphere."
Read more
Noviogel acts as a novel wounds dressing
Full-thickness dorsal skin wounds in mice were treated with Noviogel for 3 and 7 days.
Read more
Dutch Heart Foundation, UMC Groningen and Pivot Park Screening Centre collaborate on heart failure High number of SMEs benefit greatly from the European Lead Factory
Scientists from UMC Groningen and Pivot Park Screening Centre have started a study with the objective to prevent one of...
Read more
A cup of coffee with … Sander van Asbeck
“It is our mission to develop the next generation of (nano)medicines; low in side-effects and high in efficacy."
Read more
NTRC expands OncolinesProfiler™ reference compound database to 162 anti-cancer agents
New compounds include Herceptin® (trastuzumab), the antibody drug conjugate Kadcyla®, the SUMOylation inhibitor ML-792, and the selective BTK inhibitor acalabrutinib.
Read more
Aduro Biotech Announces Initiation of Phase 1b Clinical Trial in Non-Small Cell Lung Cancer
Aduro Biotech Announces Initiation of Phase 1b Clinical Trial in Non-Small Cell Lung Cancer under Janssen Strategic Partnership for ADU-214 in Combination with Nivolumab
Read more
Pivot Park is one of the fastest growing campuses in the Netherlands
Met een groei van 57% aan werkgelegenheid tussen 2014 en 2018 behoort het Pivot Park tot de sterkst groeiende campussen in Nederland.
Read more
Binding term sheet for allogeneic CAR-NK therapies
MolMed and Glycostem announce the execution of a binding term sheet for the development and manufacturing of allogeneic CAR-NK therapies.
Read more
A cup of coffee with … Kelly Knaapen-Arts
Arnold & Siedsma was one of the first companies that became part of the Pivot Park community in 2012.
Read more